

Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2020-21/048

February 11, 2021

To,

Listing Department

BSE Ltd

1st Floor, New Trade Wing,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001.

Scrip Code: 532637

Listing Department

**National Stock Exchange of
India Limited**

"Exchange Plaza", 5th Floor,

Plot No. C-1, Block G,

Bandra - Kurla Complex,

Bandra(E), Mumbai - 400 051

Symbol: MANGALAM

Sub: Un-Audited Financial Results for the Quarter ended December 31, 2020

Dear Sir / Madam,

With reference to above mentioned subject and further to our letter reference no. MDOL/CS-SE/2020-21/047 of even date, we would like to inform you that we had submitted an Un-audited Financial Results for the quarter ended on December 31, 2020. However, in the covering letter we had erroneously mentioned the subject as Un-Audited Financial Results for the Quarter ended December 31, 2021 instead of the subject Un-Audited Financial Results for the Quarter ended December 31, 2020.

This is typographical error. Kindly read the subject line of letter reference no. MDOL/CS-SE/2020-21/047 as Un-audited Financial Results for the quarter ended December 31, 2020. Please find attached the Un-Audited Financial Results for the Quarter ended December 31, 2020.

Please note that there are no changes in the Financial Results / figures for the quarter ended December 31, 2020.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For **Mangalam Drugs & Organics Limited**

Geeta Karira

Company Secretary & Compliance Officer



Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2020-21/047

February 11, 2021

To,

Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.
Scrip Code: 532637

Listing Department
National Stock Exchange of
India Limited
"Exchange Plaza", 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051
Symbol: MANGALAM

Sub: Un-Audited Financial Results for the Quarter ended December 31, 2021

Dear Sir / Madam,

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we are enclosing herewith Un-audited Financial Results on Standalone basis for the quarter ended December 31, 2020 along with Limited Review Report of the said period in the prescribed form which have been taken on record and approved by the Board of Directors of the Company in its meeting held today i.e. Thursday, February 11, 2021 at Mumbai.

Kindly note that meeting of Board of Directors commenced at 12:00 P.M. and concluded at 3:30 P.M.


Further please note that the Company has made necessary arrangement to publish the same in newspapers as required under Listing Regulations.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For Mangalam Drugs & Organics Limited


Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086



Un-Audited Financial Results for the Quarter & Nine Months Ended 31st December 2020 approved and taken on record by the Board at their meeting dated 11th February, 2021

Sr.No	Particulars	Quarter Ended			Year to Date		(Rs. In Lacs)
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	31.03.2020 Audited
A) Part-1 Statement of Un-Audited Financial Results for the Quarter & Nine Months Ended December 31, 2020							
1	Revenue from Operations	8,868.73	9,702.57	6,194.36	28,935.36	19,425.90	28,235.36
2	Other Income	126.78	68.42	65.90	260.68	72.79	118.12
3	Total Revenue(1+2)	8,995.51	9,770.99	6,260.26	29,196.04	19,498.69	28,353.48
4	Expenses						
	(a) Cost of Materials Consumed	5,354.36	7,859.07	3,744.41	20,132.79	12,527.59	17,807.14
	(b) Purchase of Stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in Inventories of Finished Goods, Stock-in-trade & Work in progress	278.35	(1,765.02)	408.34	(1,103.09)	643.45	1,727.66
	(d) Employee Benefits Expenses	741.19	713.17	635.28	2,140.99	1,898.75	2,604.41
	(e) Finance Costs	234.82	260.42	254.45	711.04	794.18	1,040.47
	(f) Depreciation & amortization expenses	233.36	226.54	205.75	666.00	612.17	821.78
	(g) Other Expenses	1,234.50	1,133.26	910.46	3,380.52	2,702.70	3,726.81
	Total Expenses	8,076.58	8,427.44	6,158.69	25,928.25	19,178.84	27,728.27
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	918.93	1,343.55	101.57	3,267.79	319.85	625.21
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	918.93	1,343.55	101.57	3,267.79	319.85	625.21
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	918.93	1,343.55	101.57	3,267.79	319.85	625.21
10	Tax Expenses						
	Current Tax	204.42	384.86	11.85	774.37	75.41	110.10
	Less: MAT credit entitlement / reversal	71.09	-150.01	-75.41	(88.25)	-75.41	-104.74
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	(205.40)
11	Net Profit(+)/Loss(-) after Tax (9-10)	643.42	1,108.70	165.13	2,581.67	319.85	825.25
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	(33.42)	(59.87)	0.87	(100.28)	2.00	2.32
13	Total Comprehensive Income	610.00	1,048.83	166.00	2,481.39	321.85	827.57
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity						8,811.05
16	Earnings Per Share (EPS) (of Rs 10/-each)not annualised):						
	(a) Basic	4.07	7.00	1.04	16.31	2.02	5.21
	(b) Diluted	4.07	7.00	1.04	16.31	2.02	5.21

Notes :


- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on February 11, 2021. The Statutory Auditors have expressed a modified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- The Code on Social Security, 2020('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent December 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- Deffered Tax calculation as per Ind AS 12 is considered by the Company on annual basis
- Earlier period figures have been regrouped/ rearranged wherever necessary.

Place: Mumbai
Date: 11th February, 2021



On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Chairman & Managing Director
(DIN:01240086)



Limited Review Report on Unaudited Quarterly and Nine months ended Standalone Financial Results of Mangalam Drugs & Organics Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

TO THE BOARD OF DIRECTORS OF
Mangalam Drugs & Organics Limited

We have reviewed the accompanying Statement of unaudited standalone financial results of **Mangalam Drugs & Organics Limited** ("Company") for the quarter and nine months ended 31st December 2020 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed, under Section 133 of the Companies Act, 2013, and accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to the financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Emphasis of Matter

Hon'ble Securities Appellate Tribunal granted the interim reliefs vide its Order dated December 10, 2020 (SAT Interim Order) by directing that the effect and operation of the order passed by Securities and Exchange Board of India (SEBI) through its whole-time member, Mr. Ananta Barua, dated September 22, 2020 shall remain stayed provided the Company and entities / individuals part of the promoter and promoter group (appellants) deposit a sum of Rs. 25 Lakhs before the SEBI within 4 (four) weeks from the date of SAT Interim Order. The amount so deposited shall be subject to the result of the appeal. The application for stay filed by appellants was disposed of. Accordingly, Appellants had deposited a sum of Rs. 25 Lakhs before the SEBI (including Rs. 2.92 Lakhs deposited by the Company).

Our opinion is not modified in respect of this matter.



Basis for Qualified conclusion:

Based on our review and explanation and information provided to us by the Management, deferred tax as per Ind AS 12 is considered on annual basis and hence impact of the same is not ascertainable on the Profit & Loss account and Assets and Liabilities as on 31st Dec 2020.

Qualified Conclusion:

Based on our review conducted as above, except for the matter prescribed in the Basis for Qualified Opinion paragraph nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Batliboi & Purohit
Chartered Accountants
Firm Registration No.: 101048W



Raman Hangekar
Partner
Membership No: 030615
UDIN: 21030615AAAABM3504

Date: February 11, 2021
Place: Mumbai



BRANCHES :

NAVI MUMBAI : 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478
DELHI : 505, Nirmal Tower, 26, Barakhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200